Physician profile
David Anthony Hager
NPI 1790858579
$6,947.02
in general payments reported to CMS, 2019-2025
47 companies · $75.75 in 2025
The $75.75 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $321 · 2020: $644 · 2021: $1,553 · 2022: $1,351 · 2023: $1,669 · 2024: $1,334 · 2025: $75.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,078.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,078.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $929.31 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $609.63 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $592.20 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $517.62 | 2019-2024 | Xarelto, Spravato |
| Lilly USA, LLC | $498.88 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $417.90 | 2020-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $399.02 | 2019-2024 | Fasenra, Breztri, Airsupra |
| Pfizer INC. | $277.35 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $225.84 | 2022-2024 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $184.50 | 2019-2024 | Xifaxan, Trulance |
| Nestle Healthcare Nutrition INC. | $174.07 | 2020-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $168.43 | 2022 | |
| Astellas Pharma US INC | $152.66 | 2020-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $142.68 | 2021-2024 | |
| Amgen INC. | $134.78 | 2019-2024 | Repatha, Evenity, Prolia |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hager listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.